MyFinsight
Home
Blog
About
Contact
Proceeds from the
issuance of common stock...
$83,154K
Proceeds from the
issuance of common stock...
$5,041K
Proceeds from exercises
of stock options
$17K
Net cash provided by
financing activities
$88,212K
Net decrease in
cash, cash...
$39,873K
Canceled cashflow
$48,339K
Proceeds from maturities
of marketable...
$13,000K
Stock-based compensation
expense
$2,731K
Accounts receivable
-$969K
Depreciation expense
$380K
Non-cash lease expense
$242K
Other non-current
assets
-$132K
Prepaid expenses and
other current assets
-$54K
Net amortization of
premiums and discounts on...
-$2K
Net cash provided by
(used in) investing...
-$32,240K
Net cash used in
operating activities
-$16,074K
Effect of exchange rate
changes on cash, cash...
-$25K
Canceled cashflow
$13,000K
Canceled cashflow
$4,510K
Purchases of marketable
securities
$45,219K
Net loss
-$19,625K
Purchases of property and
equipment
$21K
Operating lease
liabilities
-$601K
Accrued expenses and
other current...
-$205K
Accounts payable
-$153K
Back
Back
Cash Flow
Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO)
source: myfinsight.com